ClinicalTrials.gg
CompletedNCT06284837SAFER-TAVIUpdated Aug 12, 2026

Secondary Access - FEmoral or Radial in Transcatheter Aortic Valve Implantation?

An interventional study of Access site in Valve Stenoses, Aortic, sponsored by The Alfred. Completed at 3 sites in Australia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-12.

Sponsored by The Alfred · Not applicable, Interventional, and Other

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
542
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 35 studies in Aortic Valve Stenosis with a site in Australia — 10 open to participants now, 15 under way, none of them phase 3. Aortic Valve Stenosis · Australia.

Enrollment
11th of 28
542 · median 358
Started
2024
with 1 other
No phase
28 of 35
8 open now
Registered
30th of 35
by date
Lead sponsor
2 of 35
The Alfred

Among the 35 studies in Aortic Valve Stenosis with a site in Australia, this one is the 11th largest by enrollment of the 28 interventional ones that give a count, is one of 2 that started in 2024, is one of 28 with no phase, and was the 30th registered.

Aortic Valve Stenosis

1,028 studies on the registry are indexed under Aortic Valve Stenosis; 295 are open to participants now.

Browse Aortic Valve Stenosis studies →

Open to participants now

10 of the 35 studies in Aortic Valve Stenosis with a site in Australia are open now. Recruiting first, the newest first:

5 more — sign in →

All 10 open studies →

A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →

Who these studies take

Of the 209 Aortic Valve Stenosis studies recruiting now, 163 (78%) set no upper age limit and 9 (4%) stop at 75 or younger; 24 take children under 18; 14 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 35 studies in Aortic Valve Stenosis with a site in Australia, or all of them as a file.
02

Study summary

Transcatheter aortic valve implantation (TAVI) is a well-known safe and effective treatment for anatomically suitable patients with severe aortic stenosis (AS). Despite rapid improvements in TAVI technique and technology, vascular and bleeding complications from both primary and secondary access sites remain significant, with approximately 25% of access related complications thought to be related to secondary access. The transfemoral route remains the most common approach for primary access during TAVI due to proven safety and efficacy. Secondary access during TAVI, which is needed for angiographic guidance, has drawn little attention in randomised trials of TAVI. In coronary intervention, the radial approach is now preferred due to high quality evidence suggesting lower bleeding and vascular complications compared to the femoral approach. Whilst randomised control trials comparing radial vs femoral as secondary access are lacking in the TAVI setting, observational studies comparing the two secondary access routes have shown a lower risk of bleeding and vascular complications with radial compared to femoral access. A systematic review of all the major observational trials also suggests that radial access might reduce risk of bleeding, vascular complications, and even 30-day mortality, but these data are limited to observational trials and there are no randomised controlled data to confirm these findings. Accordingly, we aim to undertake a multicentre, randomised controlled trial among patients undergoing transfemoral TAVI to assess if radial secondary access is superior to femoral secondary access.

03

Conditions studied

  • Valve Stenoses, Aortic

Keywords

  • TAVI
  • TAVR
  • transcatheter aortic valve replacement
  • transcatheter aortic valve implantation
  • aortic stenosis
  • vascular access
  • primary access
  • secondary access
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age >18 years
  • Undergoing transfemoral TAVI with any commercially available transcatheter heart valve
  • Suitable radial and secondary femoral access

Exclusion criteria

Exclusion Criteria:

  • Primary arterial access via surgical cut-down
  • Inadequate contralateral femoral artery access and/or bilateral radial artery access as determined by the interventional cardiologist
  • Previously failed attempt to access bilateral radial arteries.
  • Patient on hemodialysis
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
542 participants (actual)

Study arms

  • Active comparator
    Radial secondary access

    Other: Access site

  • Active comparator
    Femoral secondary access

    Other: Access site

Interventions

  • OtherAccess site

    The SAFER-TAVI trial is randomized study comparing secondary access via a transradial versus transfemoral approach among patients undergoing transfemoral TAVI for aortic valve disease. Secondary access is gained along with primary access at the commencement of the TAVI procedure and is used for aortography before and after valve deployment and for assessment of the primary femoral access site after closure to confirm haemostasis. For patients assigned to radial access, the radial sheath will be removed using a radial band at the end of the procedure. For patients assigned to femoral access, the puncture site will be obtained under ultrasound guidance and fluoroscopic landmark identification. Unless contraindicated, the use of vascular closure devices will be recommended for all femoral cases. The choice of closure device is at the discretion of the operator. Catheters used in the access groups will be 5 or 6 French size at the discretion of the operator.

06

What researchers measure

Primary outcomes

  1. All clinically relevant bleeding and all vascular complications

    The composite of all clinically relevant bleeding (defined as Bleeding Academic Research Consortium \[BARC\] type ≥2) and vascular complications (Valve Academic Research Consortium \[VARC3\] criteria) at 30 days.

    Time frame: 30 days

Secondary outcomes

  1. All clinically relevant bleeding (BARC ≥2), overall and by access site

    Using BARC criteria

    Time frame: 30 days

  2. All vascular complications, overall and by access site

    Using VARC-3 criteria

    Time frame: 30 days

  3. All-cause death

    Using VARC-3 criteria

    Time frame: 30 days

  4. Stroke

    Using VARC-3 criteria

    Time frame: 30 days

  5. Myocardial infarction

    Using VARC-3 criteria

    Time frame: 30 days

  6. Major adverse cardiovascular events

    The composite of cardiovascular death, non-fatal myocardial infarction and non-fatal stroke

    Time frame: 30 days

  7. Length of stay post-procedure

    Length of stay post-procedure measured in time (days) from procedure to discharge

    Time frame: 30 days

  8. Overall procedure duration

    TAVI procedure duration measured in time (minutes)

    Time frame: 1 day

  9. Radiation dose

    Radiation dose measured as air kerma in milligrays

    Time frame: 1 day

  10. Conversion rate to alternative vascular access site

    Conversion rate to alternative vascular access site

    Time frame: 30 days

  11. Tertiary site utilised to treat vascular complication

    Tertiary site utilised to treat vascular complication

    Time frame: 30 days

  12. Failure to perform angiogram of primary access site at completion of TAVI

    Failure to perform angiogram of primary access site at completion of TAVI

    Time frame: 1 day

07

Study locations

3 sites
  • Alfred Health
    Melbourne, Victoria 3004, Australia
  • Epworth Healthcare
    Melbourne, Victoria 3121, Australia
  • Cabrini Health
    Melbourne, Victoria 3144, Australia
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided — Yes if ethics is approved

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2024 to primary completion in Jun 2026, 28 months.

Of 177 non-industry interventional studies with no phase under Aortic Valve Stenosis, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 79. This study's 28 months is below that.

Counting every sponsor, half of 288 studies reached it within 33 months; a quarter within 18 and three quarters within 71.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 8, 2023
First posted
Feb 29, 2024
StartActual
Feb 2, 2024
Primary completionActual
Jun 10, 2026
CompletionActual
Jun 10, 2026
Last update
Aug 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 12, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06284837
Lead sponsor
The Alfred
Collaborators
Epworth Healthcare, Cabrini Health
Responsible party
Jennifer Zhou (Principal Investigator, The Alfred) — Principal investigator
First posted
Feb 29, 2024
Start date
Feb 2, 2024
Primary completion
Jun 10, 2026
Completion
Jun 10, 2026
Last update
Aug 12, 2026

Study contacts

Antony Walton, MBBS
principal investigator · The Alfred and Epworth Healthcare
Dion Stub, MBBS, PhD
principal investigator · The Alfred and Cabrini Health

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion